Affordable Access

Access to the full text

Nonalcoholic fatty liver disease and atrial fibrillation: possible pathophysiological links and therapeutic interventions

Authors
  • Haghbin, Hossein1
  • Gangwani, Manesh Kumar2
  • Ravi, Shri Jai Kirshan3
  • Perisetti, Abhilash4
  • Aziz, Muhammad1
  • Goyal, Hemant5
  • Nawras, Ali6
  • Sodeman, Thomas6
  • 1 Department of Internal Medicine, University of Toledo Medical Center, Toledo, Ohio (Hossein Haghbin, Muhammad Aziz)
  • 2 Department of Internal Medicine, Mercy Hospital St. Louis, Missouri (Manesh Kumar Gangwani)
  • 3 Department of Internal Medicine, Guthrie Robert Packer Hospital, Pennsylvania (Shri Jai Kirshan Ravi)
  • 4 Department of Gastroenterology and Hepatology, University of Arkansas for Medical Sciences, Arkansas (Abhilash Perisetti)
  • 5 Division of Gastroenterology, The Wright Center for Graduate Medical Education, Pennsylvania (Hemant Goyal)
  • 6 Division of Gastroenterology and Hepatology, University of Toledo Medical Center, Toledo, Ohio (Ali Nawras, Thomas Sodeman), USA
Type
Published Article
Journal
Annals of Gastroenterology
Publisher
Hellenic Society of Gastroenterology
Publication Date
Oct 12, 2020
Volume
33
Issue
6
Pages
603–614
Identifiers
DOI: 10.20524/aog.2020.0550
PMID: 33162737
PMCID: PMC7599354
Source
PubMed Central
Keywords
License
Green

Abstract

Atrial fibrillation (AF) and nonalcoholic fatty liver disease (NAFLD) share common risk factors and appear to have an association. Independently, the incidence and prevalence of both diseases are on the rise. Epidemiological evidence, experimental studies and various randomized clinical trials suggest a link between the 2 entities, delineating cumulative risks and clinical strategies to improve outcomes. Dyslipidemia, insulin resistance, inflammatory milieu, and activation of the renin-angiotensin system are likely common pathophysiological mechanisms linking AF and NAFLD. In this article we review the known pathways and pathophysiology that link the 2 conditions. This review also discusses therapies that target both NAFLD and AF, such as angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, statins, metformin, and vitamin E. We further discuss other potential medications that have shown effects in NAFLD or AF through anti-inflammatory, antidiabetic, lipid-lowering, or renin-angiotensin system inhibiting effects. Future epidemiological studies are needed to establish a direct causal relationship between NAFLD and AF.

Report this publication

Statistics

Seen <100 times